Zogenix Inc. (NASDAQ:ZGNX) traded down 6.1% during trading on Wednesday . The stock traded as low as $8.69 and last traded at $8.76, with a volume of 73,268 shares trading hands. The stock had previously closed at $9.33.

Several equities research analysts have recently commented on the stock. Brean Capital reaffirmed a “buy” rating and set a $28.00 price target on shares of Zogenix in a research report on Wednesday, May 11th. Zacks Investment Research lowered shares of Zogenix from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $22.75.

The stock has a 50 day moving average of $9.18 and a 200-day moving average of $9.57. The stock’s market capitalization is $216.17 million.

Zogenix (NASDAQ:ZGNX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.05. The company earned $2.10 million during the quarter, compared to analysts’ expectations of $5.36 million. During the same quarter last year, the firm earned ($3.78) EPS. Zogenix’s revenue for the quarter was down 71.6% on a year-over-year basis. On average, equities research analysts predict that Zogenix Inc. will post ($3.24) earnings per share for the current fiscal year.

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.